Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals (MIRM) reported positive results from Cohort 2 of the PROGRESS study for ATEBRIOZ (zilurgisertib) in pediatric FOP patients aged 6 to <12. The drug reduced HO lesion volume and improved joint mobility, with no new lesions. Mirum plans an sNDA submission in H1 2027 to expand the indication. Safety findings were consistent with prior data.
How this was made
The 30-second read
Why it matters
The Phase 2 data expand the drug's label to younger children, potentially increasing market size and revenue forecasts.
Market read
Positive trial results could trigger a short‑term rally in MIRM and lift sentiment across rare‑disease biotech stocks.
What to watch
Small patient pool and limited commercial upside may cap long‑term upside.
Background
Mirum Pharmaceuticals (NASDAQ:MIRM) focuses on rare‑disease therapies; ATEBRIOZ is already FDA‑approved for patients 12+ with FOP.
Ticker impact
Mirum announced positive Phase 2 results for ATEBRIOZ in pediatric FOP patients and plans an sNDA filing in H1 2027.
upward pressure as investors price in expanded indication potential
First disclosure of pivotal trial results for a rare‑disease biotech; data are statistically significant and support a regulatory filing, which historically moves similar stocks.
Market effects
Strengthens the rare‑disease biotech sector and may boost peer valuations.
U.S. biotech market sees modest uplift.
Limited to biotech investors; no broad market effect.
Counterpoint
If the sNDA faces regulatory delays, the rally could be short‑lived.
Key entities
- CompanyMirum Pharmaceuticals, Inc.
Developer of ATEBRIOZ (zilurgisertib) for fibrodysplasia ossificans progressiva.
- CompanyIncyte
Original licensor of zilurgisertib to Mirum.
